William P. Forbes

7.0k total citations · 2 hit papers
107 papers, 4.9k citations indexed

About

William P. Forbes is a scholar working on Epidemiology, Surgery and Gastroenterology. According to data from OpenAlex, William P. Forbes has authored 107 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 27 papers in Surgery and 26 papers in Gastroenterology. Recurrent topics in William P. Forbes's work include Inflammatory Bowel Disease (24 papers), Gastrointestinal motility and disorders (21 papers) and Microscopic Colitis (19 papers). William P. Forbes is often cited by papers focused on Inflammatory Bowel Disease (24 papers), Gastrointestinal motility and disorders (21 papers) and Microscopic Colitis (19 papers). William P. Forbes collaborates with scholars based in United States, Canada and Spain. William P. Forbes's co-authors include Enoch Bortey, Audrey L. Shaw, Anthony Lembo, Mark Pimentel, Bruce S. Cutler, Salam Zakko, Craig Paterson, Steven L. Bramer, Peter Zhang and William D. Chey and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

William P. Forbes

103 papers receiving 4.7k citations

Hit Papers

Rifaximin Treatment in Hepatic Encephalopathy 2010 2026 2015 2020 2010 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rifaximin Treatment in Hepatic Encephalopathy
    2010 848 citations Fred Poordad, Samuel H. Sigal et al. profile →
  2. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
    2011 720 citations Salam Zakko, Jing Yu et al. profile →

Peers

William P. Forbes
Ross Dierkhising United States
Patompong Ungprasert United States
Laura E. Targownik Canada
A. Sidney Barritt United States
Davor Štimac Croatia
Karn Wijarnpreecha United States
Philip Schoenfeld United States
Alan L. Buchman United States
Pietro Vajro Italy
Robin Russell United Kingdom
Ross Dierkhising United States
William P. Forbes
Citations per year, relative to William P. Forbes William P. Forbes (= 1×) peers Ross Dierkhising

Countries citing papers authored by William P. Forbes

Since Specialization
Citations

This map shows the geographic impact of William P. Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William P. Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William P. Forbes more than expected).

Fields of papers citing papers by William P. Forbes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William P. Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William P. Forbes. The network helps show where William P. Forbes may publish in the future.

Co-authorship network of co-authors of William P. Forbes

This figure shows the co-authorship network connecting the top 25 collaborators of William P. Forbes. A scholar is included among the top collaborators of William P. Forbes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William P. Forbes. William P. Forbes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rubin, David T., Russell D. Cohen, William J. Sandborn, et al.. (2015). OP011. Budesonide MMX(R) 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs. Journal of Crohn s and Colitis. 9(suppl 1). S7–S7. 7 indexed citations
2.
Bull, Janet, Charles Wellman, Robert J. Israel, et al.. (2015). Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. Journal of Palliative Medicine. 18(7). 593–600. 57 indexed citations
3.
Webster, Lynn R., Darren M. Brenner, A. P. Barrett, et al.. (2015). Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. Journal of Pain Research. 8. 771–771. 17 indexed citations
4.
Bajaj, Jasmohan S., Andrew C. Barrett, Enoch Bortey, Craig Paterson, & William P. Forbes. (2014). Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Alimentary Pharmacology & Therapeutics. 41(1). 39–45. 39 indexed citations
5.
Lichtenstein, Gary R., Andrew C. Barrett, Enoch Bortey, Craig Paterson, & William P. Forbes. (2014). Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis. Inflammatory Bowel Diseases. 20(8). 1399–1406. 7 indexed citations
6.
MacArthur, Rodger D., Trevor Hawkins, Stephen J. Brown, et al.. (2013). Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study. HIV Clinical Trials. 14(6). 261–273. 29 indexed citations
7.
Sandborn, William J., Brian P. Bosworth, Salam Zakko, et al.. (2013). Budesonide Foam for Inducing Remission in Active Mild-to-moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Results of Two Randomized, Placebo-controlled Trials. The American Journal of Gastroenterology. 108. S542–S542.
8.
Lichtenstein, Gary R., Salam Zakko, Glenn L. Gordon, et al.. (2012). Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ ASA formulations: a pooled analysis from two randomised controlled trials. Alimentary Pharmacology & Therapeutics. 36(2). 126–134. 8 indexed citations
9.
10.
Mullen, Kathleen, Samuel H. Sigal, Mahdi Sheikh, et al.. (2009). 207 SAFETY OF RIFAXIMIN IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A RANDOMIZED, PHASE 3, PLACEBO-CONTROLLED CLINICAL TRIAL. Journal of Hepatology. 50. S84–S85. 4 indexed citations
11.
Pentikis, Helen S., et al.. (2007). The Effect of Multiple‐Dose, Oral Rifaximin on the Pharmacokinetics of Intravenous and Oral Midazolam in Healthy Volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(10). 1361–1369. 32 indexed citations
12.
Regensteiner, Judith G., John E. Ware, Walter J. McCarthy, et al.. (2002). Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials. Journal of the American Geriatrics Society. 50(12). 1939–1946. 170 indexed citations
13.
Thompson, Paul D., et al.. (2002). Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. The American Journal of Cardiology. 90(12). 1314–1319. 199 indexed citations
14.
Dawson, David L., Bruce S. Cutler, William R. Hiatt, et al.. (2000). A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American Journal of Medicine. 109(7). 523–530. 277 indexed citations
15.
Beebe, Hugh G., David L. Dawson, Bruce S. Cutler, et al.. (1999). A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.. PubMed. 159(17). 2041–50. 216 indexed citations
16.
Suri, Ajit, William P. Forbes, & Steven L. Bramer. (1999). Effects of CYP3A Inhibition on the Metabolism of Cilostazol. Clinical Pharmacokinetics. 37(Supplement 2). 61–68. 33 indexed citations
17.
Bramer, Steven L. & William P. Forbes. (1999). Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol. Clinical Pharmacokinetics. 37(Supplement 2). 25–32. 18 indexed citations
18.
Bramer, Steven L., William P. Forbes, & Suresh Mallikaarjun. (1999). Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease. Clinical Pharmacokinetics. 37(Supplement 2). 1–11. 63 indexed citations
19.
Bramer, Steven L. & William P. Forbes. (1999). Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics. Clinical Pharmacokinetics. 37(Supplement 2). 13–23. 49 indexed citations
20.
Suri, Ajit, William P. Forbes, & Steven L. Bramer. (1998). Pharmacokinetics of Multiple‐Dose Oral Cilostazol in Middle‐Age and Elderly Men and Women. The Journal of Clinical Pharmacology. 38(2). 144–150. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ross Dierkhising Breakdown of academic impact, for papers by Patompong Ungprasert Breakdown of academic impact, for papers by Laura E. Targownik Breakdown of academic impact, for papers by A. Sidney Barritt Breakdown of academic impact, for papers by Davor Štimac Breakdown of academic impact, for papers by Karn Wijarnpreecha Breakdown of academic impact, for papers by Philip Schoenfeld Breakdown of academic impact, for papers by Alan L. Buchman Breakdown of academic impact, for papers by Pietro Vajro Breakdown of academic impact, for papers by Robin Russell
Rankless by CCL
2026